Inactive Instrument

Highlights IVERIC bio, Inc.

Equities

ISEE

US46583P1021

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

IVERIC bio, Inc. Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY? (avacincaptad pegol intravitreal solution) for Geographic Atrophy	23-09-18	CI
European Medicines Agency Accepts Iveric Bio's Marketing Authorization Application for Avacincaptad Pegol for Geographic Atrophy	23-08-17	CI
Iveric Bio Receives U.S. FDA Approval for IZERVAY? (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy	23-08-04	CI
IVERIC bio's Acquisition by Astellas Pharma Completed	23-07-12	MT
Astellas Pharma Completes $5.9 Billion Acquisition of Iveric bio	23-07-11	MT
Astellas US Holding, Inc. completed the acquisition of IVERIC bio, Inc. from BlackRock, Inc., Deep Track Capital, LP, The Vanguard Group, Inc. and others.	23-07-10	CI
Analysis-Amgen's antitrust woes spur wider pharmaceutical deal fears	23-05-17	RE
IVERIC bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
IVERIC Bio Shares Jump on $5.9 Billion Deal to be Acquired by Astellas Pharma	23-05-01	MT
Fed Policy Statement Eyed as Exchange-Traded Funds, Equity Futures Slip Pre-Bell Monday	23-05-01	MT
North American Morning Briefing: Stock Futures Waver as Regulators Seize First Republic	23-05-01	DJ
Iveric Bio to be Acquired by Astellas Pharma in $5.9 Billion Deal	23-05-01	MT
Astellas Pharma to acquire Iveric Bio in USD5.9 billion deal	23-05-01	AN
Astellas Pharma to Buy Iveric Bio for About $5.9 Billion	23-04-30	DJ
Japan's Astellas to buy Iveric Bio for $5.9 bln to expand eyesight treatments	23-04-30	RE
Astellas Pharma buys Iveric Bio for $5.9 billion	23-04-30	RE
Astellas US Holding, Inc. entered into a definitive agreement to acquire IVERIC bio, Inc. from BlackRock, Inc., Deep Track Capital, LP, The Vanguard Group, Inc. and others for $5.6 billion.	23-04-29	CI
IVERIC bio Announces New Functional Vision Loss Reduction Data from Avacincaptad Pegol GATHER Trials Presented at ARVO Annual Meeting	23-04-23	CI
Iveric Bio Posts Wider Q4 Loss	23-03-01	MT
IVERIC bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights IVERIC bio, Inc.

Equities

ISEE

US46583P1021

Highlights

Filters